Skip to main content
. 2017 Aug 2;60(11):2139–2147. doi: 10.1007/s00125-017-4384-2

Fig. 3.

Fig. 3

Archived TrialNet samples distributed to perform ancillary studies. (a) The number of TrialNet archived samples distributed to perform ancillary studies are shown according to the focus of the ancillary study (immunity [further subdivided into those focused on T cells, B cells and autoantibodies (Aab), and innate immunity and inflammation (innate/inflamm)], ‘omics’ and beta cells). TrialNet studies from which samples were collected are indicated (blue bars, TN01, Pathway to Prevention study; orange bars, all other TrialNet studies). (b) The number of TrialNet archived samples distributed to perform ancillary studies are shown according to the focus of the ancillary study (immunity [further subdivided into those focused on T cells, B cells and Aab, and innate/inflamm], ‘omics’ and beta cells) and by type of sample distributed (serum; peripheral blood mononuclear cells [PBMCs], plasma, DNA and RNA)